144 related articles for article (PubMed ID: 2527275)
1. Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents.
Kovacs JA; Allegra CJ; Beaver J; Boarman D; Lewis M; Parrillo JE; Chabner B; Masur H
J Infect Dis; 1989 Aug; 160(2):312-20. PubMed ID: 2527275
[TBL] [Abstract][Full Text] [Related]
2. Microculture screening assay for primary in vitro evaluation of drugs against Pneumocystis carinii.
Comley JC; Mullin RJ; Wolfe LA; Hanlon MH; Ferone R
Antimicrob Agents Chemother; 1991 Oct; 35(10):1965-74. PubMed ID: 1759815
[TBL] [Abstract][Full Text] [Related]
3. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
Piper JR; Johnson CA; Krauth CA; Carter RL; Hosmer CA; Queener SF; Borotz SE; Pfefferkorn ER
J Med Chem; 1996 Mar; 39(6):1271-80. PubMed ID: 8632434
[TBL] [Abstract][Full Text] [Related]
4. 2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Rosowsky A; Mota CE; Wright JE; Freisheim JH; Heusner JJ; McCormack JJ; Queener SF
J Med Chem; 1993 Oct; 36(21):3103-12. PubMed ID: 8230096
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents.
Gangjee A; Shi J; Queener SF; Barrows LR; Kisliuk RL
J Med Chem; 1993 Oct; 36(22):3437-43. PubMed ID: 8230134
[TBL] [Abstract][Full Text] [Related]
6. 6,7-disubstituted 2,4-diaminopteridines: novel inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Jackson HC; Biggadike K; McKilligin E; Kinsman OS; Queener SF; Lane A; Smith JE
Antimicrob Agents Chemother; 1996 Jun; 40(6):1371-5. PubMed ID: 8726003
[TBL] [Abstract][Full Text] [Related]
7. Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate.
Kovacs JA; Allegra CJ; Swan JC; Drake JC; Parrillo JE; Chabner BA; Masur H
Antimicrob Agents Chemother; 1988 Apr; 32(4):430-3. PubMed ID: 2967669
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
Rosowsky A; Papoulis AT; Forsch RA; Queener SF
J Med Chem; 1999 Mar; 42(6):1007-17. PubMed ID: 10090784
[TBL] [Abstract][Full Text] [Related]
9. In vitro effects of folate inhibitors on Toxoplasma gondii.
Derouin F; Chastang C
Antimicrob Agents Chemother; 1989 Oct; 33(10):1753-9. PubMed ID: 2531568
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Pneumocystis carinii dihydropteroate synthetase by para-acetamidobenzoic acid: possible mechanism of action of isoprinosine in human immunodeficiency virus infection.
Kovacs JA; Powell F; Voeller D; Allegra CJ
Antimicrob Agents Chemother; 1993 Jun; 37(6):1227-31. PubMed ID: 7687120
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity and structure-selectivity studies on diaminoquinazolines and other inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Rosowsky A; Hynes JB; Queener SF
Antimicrob Agents Chemother; 1995 Jan; 39(1):79-86. PubMed ID: 7695334
[TBL] [Abstract][Full Text] [Related]
12. 2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Rosowsky A; Papoulis AT; Queener SF
J Med Chem; 1998 Mar; 41(6):913-8. PubMed ID: 9526565
[TBL] [Abstract][Full Text] [Related]
13. A radiometric method for objectively screening large numbers of compounds against Pneumocystis carinii in vitro.
Comley JC; Mullin RJ; Wolfe LA; Hanlon MH; Ferone R
J Protozool; 1991; 38(6):144S-146S. PubMed ID: 1818144
[TBL] [Abstract][Full Text] [Related]
14. Pteroylpolyglutamate synthesis by lung- and culture-derived Pneumocystis carinii.
Hong YL; Bartlett MS; Queener S; Smith JW; Shaw M; Meshnick SR
FEMS Microbiol Lett; 1995 Dec; 134(2-3):251-4. PubMed ID: 8586276
[TBL] [Abstract][Full Text] [Related]
15. Biological profile and response to anti-pneumocystis agents of Pneumocystis carinii in cell culture.
Pifer LL; Pifer DD; Woods DR
Antimicrob Agents Chemother; 1983 Nov; 24(5):674-8. PubMed ID: 6607029
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia.
Kovacs JA; Allegra CJ; Kennedy S; Swan JC; Drake J; Parrillo JE; Chabner B; Masur H
Am J Trop Med Hyg; 1988 Nov; 39(5):491-6. PubMed ID: 2973755
[TBL] [Abstract][Full Text] [Related]
17. 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
Rosowsky A; Mota CE; Queener SF; Waltham M; Ercikan-Abali E; Bertino JR
J Med Chem; 1995 Mar; 38(5):745-52. PubMed ID: 7877140
[TBL] [Abstract][Full Text] [Related]
18. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent.
Allegra CJ; Kovacs JA; Drake JC; Swan JC; Chabner BA; Masur H
J Exp Med; 1987 Mar; 165(3):926-31. PubMed ID: 2950200
[TBL] [Abstract][Full Text] [Related]
19. Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs.
Broughton MC; Queener SF
Antimicrob Agents Chemother; 1991 Jul; 35(7):1348-55. PubMed ID: 1929292
[TBL] [Abstract][Full Text] [Related]
20. Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii.
Kovacs JA; Allegra CJ; Chabner BA; Swan JC; Drake J; Lunde M; Parrillo JE; Masur H
J Infect Dis; 1987 May; 155(5):1027-32. PubMed ID: 2951446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
